Kwality Pharmaceuticals gets nod to start pre-clinical toxicity studies for Erythropoietin product

02 Jan 2025 Evaluate

Kwality Pharmaceuticals has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD).

This milestone marks a significant step forward in its commitment to expanding its biologics portfolio and addressing critical healthcare needs. With this approval, the company is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal. 

Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.


Kwality Pharma Share Price

895.70 7.70 (0.87%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×